UCB SA (UCBJF)

76.00 0.00 (0.00%) At close: 10:19AM EDT

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jean-Christophe Tellier	CEO & Exec. Director	4.34M	N/A	1959
Ms. Sandrine Dufour CFA	Exec. VP & CFO	N/A	N/A	1966
Ms. Kirsten Lund-Jurgensen	Exec. VP of Supply & Technology Solutions	N/A	N/A	1959
Dr. Dhavalkumar D. Patel M.D., Ph.D.	Exec. VP & Chief Scientific Officer	N/A	N/A	1961
Mr. William J. Silbey	Exec. VP & Gen. Counsel	N/A	N/A	1959
Mr. Jean-Luc Fleurial	Exec. VP & Chief HR Officer	N/A	N/A	1965
Prof. Iris Low-Friedrich	Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices	N/A	N/A	1960
Mr. Emmanuel Caeymaex	Exec. VP of Immunology Solutions & Head of US	N/A	N/A	1969
Mr. Charl van Zyl	Exec. VP of Neurology Solutions & Head of EU/International	N/A	N/A	1967
Ms. Caroline Vancoillie	Chief Accounting Officer & CFO of Patient Value Functions	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Corporate governance

UCB SA’s ISS governance QualityScore as of 31 July 2022 is 3. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.